Arbutus Biopharma Corp reports results for the quarter ended March 31 - Earnings Summary

Arbutus Biopharma

14/05/2025 13:31

Arbutus Biopharma Corp ABUS.OQ reported a quarterly adjusted loss of 13 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -10 cents.  The mean expectation of five analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -13 cents to -9 cents per share.

Revenue rose 15.1% to $1.76 million from a year ago; analysts expected $1.78 million.

Arbutus Biopharma Corp's reported EPS for the quarter was a loss of 13 cents​.

The company reported a quarterly loss of $24.53 million.

Arbutus Biopharma Corp shares had fallen by 8.6% this quarter and lost 2.4% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 29.2% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Arbutus Biopharma Corp is $5.00

This summary was machine generated from LSEG data May 14 at 12:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.10
-0.13
Missed
Dec. 31 2024
-0.08
-0.07
Beat
Sep. 30 2024
-0.09
-0.09
Met
Jun. 30 2024
-0.10
-0.11
Missed